NASDAQ · SUPN

Supernus Pharmaceuticals, Inc.

$46.20 -$0.99 (-2.10%) 1D After hours
Session Pulse Overnight session 1 mentions on Wed No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$2.74B
Market cap
—
P/E · TTM
$776.83M
Revenue · TTM
−$29.02M
Net income
EPS · TTM $-0.52
Dividend yield —
Free cash flow $82.25M
Beta · 1Y 0.63
EBITDA · TTM $48.16M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    A material event was filed (Form 8-K).

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.74B
Enterprise value—
Shares outstanding58.0M
52-wk range$32.83 – $59.68
Avg volume · 20D514.7K
Net cash —
Book value / share$19.28
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Supernus Pharmaceuticals, Inc.
IPO dateMay 1, 2012
Employees778

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S3.53
P/FCF33.30
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating -6.3%
Net -3.7%
FCF 10.6%
ROE / ROIC -2.7% · -3.3%

Financial Health

Current ratio1.96
Quick ratio1.66
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$357.65M

Cash Flow · TTM

Operating CF $83.26M
Capex −$1.01M
Free cash flow $82.25M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

5.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings